...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tuberculosis Research and Treatment >Mycobacterium bovisBacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control
【24h】

Mycobacterium bovisBacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control

机译：牛分枝杆菌杆菌卡介苗作为全球传染病控制的疫苗载体

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mycobacterium bovisbacille Calmette-Guérin (BCG) is the only available vaccine for tuberculosis (TB). Although this vaccine is effective in controlling infantile TB, BCG-induced protective effects against pulmonary diseases in adults have not been clearly demonstrated. Recombinant BCG (rBCG) technology has been extensively applied to obtain more potent immunogenicity of this vaccine, and several candidate TB vaccines have currently reached human clinical trials. On the other hand, recent progress in the improvement of the BCG vector, such as the codon optimization strategy and combination with viral vector boost, allows us to utilize this bacterium in HIV vaccine development. In this paper, we review recent progress in rBCG-based vaccine studies that may have implications in the development of novel vaccines for controlling global infectious diseases in the near future.
机译：牛分枝杆菌Calmette-Guérin（BCG）是唯一可用于结核病（TB）的疫苗。尽管该疫苗可有效控制婴儿结核病，但尚未明确证明BCG诱导的针对成年人肺部疾病的保护作用。重组BCG（rBCG）技术已被广泛应用，以使该疫苗具有更强的免疫原性，并且几种候选结核病疫苗目前已进入人体临床试验。另一方面，最近在改进BCG载体方面的进展，例如密码子优化策略以及与病毒载体加强剂的结合，使我们能够利用这种细菌开发HIV疫苗。在本文中，我们回顾了基于rBCG的疫苗研究的最新进展，这些进展可能对在不久的将来控制全球传染病的新型疫苗的开发产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号